Analyst Price Targets — ANIP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:32 am | Vamil Divan | Guggenheim | $124.00 | $85.29 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim |
| October 9, 2025 1:23 pm | — | Truist Financial | $90.00 | $91.63 | TheFly | ANI Pharmaceuticals price target raised to $90 from $77 at Truist |
| September 17, 2025 2:17 pm | Brandon Folkes | H.C. Wainwright | $121.00 | $95.36 | TheFly | ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright |
| September 8, 2025 11:46 am | Vamil Divan | Guggenheim | $114.00 | $95.20 | TheFly | ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim |
| August 8, 2025 3:00 pm | David Amsellem | Piper Sandler | $94.00 | $81.13 | TheFly | ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler |
| March 5, 2025 1:58 pm | — | Guggenheim | $86.00 | $59.68 | TheFly | ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim |
| September 18, 2024 9:14 am | Gary Nachman | Raymond James | $83.00 | $61.23 | TheFly | ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James |
| September 11, 2024 6:06 am | Les Sulewski | Truist Financial | $60.00 | $55.48 | TheFly | ANI Pharmaceuticals downgraded to Hold from Buy at Truist |
| June 26, 2024 6:36 am | Oren Livnat | H.C. Wainwright | $94.00 | $65.49 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright |
| May 13, 2024 7:17 am | Oren Livnat | H.C. Wainwright | $87.00 | $68.06 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $87 at H.C. Wainwright |
Latest News for ANIP
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SUBCY, MKSI, ANIP, AHKSY and ADSK have been added to the Zacks Rank #1 (Strong Buy) List on April 16, 2026.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00. Following the transaction, the vice president directly owned 78,890 shares of the company's stock,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANIP.
U.S. House Trading
No House trades found for ANIP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.